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Abstract
Background: Trauma is the leading cause of morbidity and mortality in children in the United States. The
antifibrinolytic drug tranexamic acid (TXA) improves survival in adults with traumatic hemorrhage, however,
the drug has not been evaluated in a clinical trial in severely injured children. We designed the Traumatic
Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC) trial to evaluate the feasibility of conducting a
confirmatory clinical trial that evaluates the effects of TXA in children with severe trauma and hemorrhagic injuries.
Methods: Children with severe trauma and evidence of hemorrhagic torso or brain injuries will be randomized to
one of three arms: (1) TXA dose A (15 mg/kg bolus dose over 20 min, followed by 2 mg/kg/hr infusion over 8 h),
(2) TXA dose B (30 mg/kg bolus dose over 20 min, followed by 4 mg/kg/hr infusion over 8 h), or (3) placebo. We
will use permuted-block randomization by injury type: hemorrhagic brain injury, hemorrhagic torso injury, and
combined hemorrhagic brain and torso injury. The trial will be conducted at four pediatric Level I trauma centers.
We will collect the following outcome measures: global functioning as measured by the Pediatric Quality of Life
(PedsQL) and Pediatric Glasgow Outcome Scale Extended (GOS-E Peds), working memory (digit span test), total
amount of blood products transfused in the initial 48 h, intracranial hemorrhage progression at 24 h, coagulation
biomarkers, and adverse events (specifically thromboembolic events and seizures).
Discussion: This multicenter trial will provide important preliminary data and assess the feasibility of conducting
a confirmatory clinical trial that evaluates the benefits of TXA in children with severe trauma and hemorrhagic
injuries to the torso and/or brain.
Trial registration: ClinicalTrials.gov registration number: NCT02840097. Registered on 14 July 2016.
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Background
Trauma is the leading cause of morbidity and mortality in
children in the United States [1]. Deaths from pediatric
trauma are primarily from direct injury to critical organs
(brain, heart, lungs) or hemorrhage into the thoracic and/
or abdominal cavities. In the initial 24 h after injury,
hemorrhage is the leading cause of death [2]. The degree
of hemorrhage is influenced by both the extent of injury
to the structures and the occurrence of trauma-induced
coagulopathy. Traumatic coagulopathy is common after
severe injury, particularly in patients with brain injuries,
acidosis, and/or shock; it independently increases the risk
of morbidity and mortality [3–6]. Nearly 30% of injured
children admitted to the hospital have abnormalities of
routine clotting parameters and 6% have markedly abnor-
mal values [7].
Hyperfibrinolysis, or the premature and excessive break-
down of blood clots, is largely driven by increased plasmin
generation after tissue injury and is a major component of
traumatic coagulopathy [8, 9]. As measured by thromboe-
lastography (TEG) testing, hyperfibrinolysis occurs in 24%
of severely injured children and increases the risk for
death sixfold compared to children without hyperfibrino-
lysis [10]. Hyperfibrinolysis is also associated with the
need for lifesaving interventions and the need for blood
product transfusions in severely injured children [11].
Tranexamic acid (TXA) is an antifibrinolytic lysine
analog that inhibits plasminogen activation. Plasmin is
central to fibrinolysis as it catalyzes the dissolution of fi-
brin clots. Premature and excessive fibrinolysis is a
prominent characteristic of traumatic coagulopathy
and hemorrhage progression due to elevated levels of
tissue plasminogen activator (tPA) commonly seen
after traumatic injuries, particularly traumatic brain
injuries (TBI) [12].
Recent evidence in injured adults indicates that treat-
ment with TXA decreases the risk of mortality following
traumatic hemorrhage [13]. The Clinical Randomization
of an Antifibrinolytic in Significant Haemorrhage-2
(CRASH-2) trial randomized 20,211 adult trauma pa-
tients at risk for significant hemorrhage to TXA or pla-
cebo. If administered within 3 h of injury, TXA reduced
the risk of death from bleeding by approximately one
third [14]. Furthermore, TXA had an excellent safety
profile and was found to be cost-effective for use in
these injured adult patients [15]. Based on the results of
the CRASH-2 trial, administration of TXA is considered
standard of care for severely injured adults with
hemorrhagic trauma and is included on the World
Health Organization’s (WHO) list of essential drugs.
A similar clinical trial has not been conducted in chil-
dren with hemorrhagic injuries. We previously demon-
strated that TXA is rarely given for injured children in
US children’s hospitals [16]. Data regarding TXA use in
children is mostly limited to those undergoing certain
elective surgeries, specifically cardiac surgery [17–20],
with some small studies in children undergoing spinal
and craniofacial surgeries [17], and across a wide range
of doses [17, 21]. These data suggest that perioperative
administration of TXA decreases blood transfusion
requirements in children. Furthermore, these studies
suggest an excellent safety profile for TXA in children
[17–20]. The type of traumatic insult and degree of in-
flammation and its impact on coagulation in patients
with these elective surgeries, however, is likely different
than that following hemorrhage from trauma.
Based on the TXA studies in injured adults and the
evidence of safety and effectiveness in children undergo-
ing non-traumatic surgical procedures, there is great po-
tential that TXA may safely improve clinical outcomes
in injured children. Not surprisingly, determining if
TXA is beneficial and safe in injured children is a top
priority for several stakeholders [6, 22–24]. To address
this clinical question, we will conduct a pilot trial to
demonstrate the ability to efficiently identify and enroll
children with severe trauma and hemorrhagic injuries
into a multicenter, randomized controlled trial evaluat-
ing two doses of TXA and placebo.
Methods
Study design
This pilot study is a double-blind, randomized, con-
trolled trial of children younger than 18 years with
hemorrhagic injuries to the torso and brain. We will
enroll a maximum of 40 children during the study.
Children will be randomized into one of three arms: (1)
TXA dose A (15 mg/kg bolus dose over 20 min,
followed by 2 mg/kg/hr infusion over 8 h), (2) TXA dose
B (30 mg/kg bolus dose over 20 min, followed by 4 mg/
kg/hr infusion over 8 h), and (3) normal saline placebo.
This pilot study will be conducted in preparation for a
confirmatory clinical trial of TXA administration for chil-
dren with hemorrhagic torso and/or brain injuries (Fig. 1).
SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) guidelines were followed and a
checklist completed (Additional file 1) [25].
Study setting
The pilot study will be conducted at 4 clinical sites. All
sites are American College of Surgery (ACS) verified
Level I pediatric trauma centers.
Participants
Inclusion and exclusion criteria
Children younger than 18 years with evidence of
hemorrhagic injuries to the torso and/or brain will be eli-
gible. Eligible patients will be divided into three groups
(head injury, torso injury, or head and torso injury) based
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on the inclusion criteria listed below. Patients in the com-
bined head and torso injury group must meet entry cri-
teria for both head and torso trauma. See Tables 1 and 2
for specific inclusion and exclusion criteria.
Participant screening and consent
Prior to the onset of the study and intermittently during
its course, site clinical research coordinators and emer-
gency department (ED) clinicians will be educated re-
garding the trial and trained to identify potentially
eligible patients. Patients will be identified and recruited
from the EDs of the participating centers. On arrival to
the ED, all injured children will undergo primary and
secondary surveys by the physicians providing clinical
care in the ED. Injured children will then undergo diag-
nostic testing as deemed appropriate by the treating
physicians (i.e., standard of care). These patients will be
screened by clinical research coordinators and patients
believed to be eligible will be discussed with the treating
physicians. If the patient is believed to be eligible, the
coordinator will contact the study site investigative team
to discuss eligibility. A study investigator (a clinician, de-
termined by each site) will evaluate the patient and de-
termine eligibility (Fig. 2). At the start of this pilot trial,
we enrolled patients only if written informed consent
was obtained from parents or legal guardians. After
starting the trial, however, it became evident that most
eligible patients did not have a parent or legal guardian
Table 1 Inclusion criteria for TIC-TOC trial
Penetrating Torso Trauma:
• Penetrating trauma to the chest, abdomen, neck, pelvis, or thigh with
at least one of the following:
◦ age-adjusted hypotension, or
◦ age-adjusted tachycardia despite adequate resuscitation fluids, or
◦ radiographic evidence of internal hemorrhage, or
◦ clinical suspicion of ongoing internal hemorrhage
Blunt Torso Trauma:
• Clinician suspicion of hemorrhagic blunt torso injury and at least one
of the following:
◦ age-adjusted hypotension, or
◦ persistent age-adjusted tachycardia despite adequate resuscitation
fluids
• Hemothorax on chest tube placement or imaging; or
• Clinical suspicion of hemorrhagic blunt torso injury and intraperitoneal
fluid on abdominal ultrasonography (Focused Assessment with
Sonography in Trauma; FAST); or
• Intra-abdominal injury on CT with either contrast extravasation or more
than trace intraperitoneal fluid; or
• Pelvic fracture with contrast extravasation or hematoma on abdominal/
pelvic CT scan with at least one of the following:
◦ age-adjusted tachycardia or
◦ age-adjusted hypotension
Head Trauma:
• GCS score 3 to 13 with associated intracranial hemorrhage on cranial
CT scan
Abbreviations: CT computed tomography, GCS Glasgow Coma Scale, TOC-TOC
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children
Fig. 1 Study objectives of the TIC-TOC pilot trial
Table 2 Exclusion criteria for TIC-TOC trial
Exclusion criteria include any of the below:
1. Unable to administer study drug within 3 h of traumatic event
2. Known pregnancy
3. Known prisoners
4. Known wards of the state
5. Cardiac arrest prior to randomization
6. GCS score of 3 with bilateral unresponsive pupils
7. Isolated subarachnoid hemorrhage, epidural hematoma, or diffuse
axonal injury
8. Known bleeding/clotting disorders
9. Known seizure disorders
10. Known history of severe renal impairment
11. Unknown time of injury
12. Previous enrollment into the TIC-TOC trial
13. Prior TXA for current injury
14. Non-English and non-Spanish speaking
15. Known venous or arterial thrombosis
Abbreviations: GCS Glasgow Coma Scale, TOC-TOC Traumatic Injury Clinical Trial
Evaluating Tranexamic Acid in Children, TXA tranexamic acid
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available to provide written informed consent at the time
of ED presentation and study eligibility. We therefore re-
vised the protocol to include Exception from Informed
Consent (EFIC) procedures if the parent or legal guard-
ian was not available to provide written informed con-
sent at the time of study eligibility.
Interventions
Enrolled patients will be randomized to one of three
study arms: TXA dose A, TXA dose B, or placebo. A
systematic review demonstrated substantial variability in
TXA dosing for pediatric surgical patients, ranging from
initial loading doses of 2 to 100 mg/kg intravenously
(IV), and a continuous infusion ranging from 3 to
10 mg/kg/h [17]. Doses selected for this study and ra-
tionale are as follows:
 TXA dose A arm: Patients will receive a 15 mg/kg
bolus of TXA over 20 min followed by a 2 mg/kg/h
infusion over 8 h. The maximum bolus dose is
1000 mg, the maximum rate of infusion is 50 mg/min,
and the maximum total maintenance dose is 1000 mg.
This represents a total TXA dose of 31 mg/kg. This
dosing is based on the CRASH-2 trial and has been
recommended by a prior evidence statement [26].
This dose is also estimated to inhibit approximately
80% of fibrinolysis based on prior TXA studies [27].
 TXA dose B arm: Patients will receive a 30 mg/
kg bolus of TXA over 20 min followed by a
4 mg/kg/h infusion over 8 h. The maximum bolus
dose is 2000 mg, the maximum rate of infusion is
100 mg/min, and the maximum total maintenance
dose is 2000 mg. This represents a total dose of
TXA of 62 mg/kg. This represents approximately
the 75th percentile dosage for children receiving
TXA for non-traumatic surgical procedures [16]
and is estimated to inhibit 100% of fibrinolysis
[27]. This dose is also within the range recommended
by theWHO [28] and has not demonstrated an increase
in adverse events (compared to lower doses) [17].
 Placebo arm: Patients in the placebo group will
receive a bolus dose of normal saline over 20 min
followed by a normal saline infusion over 8 h (in the
same weight- based volume as the other study arms).
The study drug will be discontinued if any of the
following occur: suspected anaphylactic reaction, se-
vere renal impairment (creatinine clearance less than
29 mL/min/1.73m2) is identified on subsequent la-
boratory measurements, withdrawal of consent by the
patient’s legal guardian or legally authorized repre-
sentative, or discovery of new information which
makes the patient ineligible to continue participation
in the study.
Fig. 2 Study enrollment procedures. Abbreviations: EFIC exception from informed consent (enrollment without in emergency scenarios when
prospective informed consent is not possible); ED emergency department; TXA tranexamic acid
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Both study patients and study team members are
blinded to the interventional arm. Blinding is provided
by the use of identical study drugs, packaging, volume,
and rates of infusion. Unblinding will not be allowed as
there is no reversal agent for TXA. Clinicians will be
asked to assume the patient has received TXA and treat
accordingly.
Randomization
Due to the narrow window of efficacy of TXA based on
the CRASH-2 trial, randomization must only minimally
delay treatment. To complete the randomization quickly,
the study intervention will be pre-assigned using a cen-
tral randomization process. Prior to enrollment at each
site, a study drug box containing a vial of masked study
drug with a numeric identification code corresponding
to the treatment assignment will be designated.
Because we will be evaluating TXA for different injury
patterns (hemorrhagic torso injury, hemorrhagic brain
injury, and combined hemorrhagic torso and brain injur-
ies), randomization will be stratified by injury pattern.
Eligible patients will be randomized into one of the three
arms in a 1:1:1 ratio (TXA dose A, TXA dose B, or pla-
cebo). We will perform permuted-block randomization
across injury pattern (i.e., torso or brain or both torso
and brain). To ensure a sufficient number of injury
types, we will limit the enrollment of patients meeting
the inclusion criteria for isolated brain injury to 20
patients (as it is anticipated these will be the most
common eligible patients evaluated at the participat-
ing sites). A patient is considered enrolled when
randomization occurs.
Outcomes
We will collect the following outcome data: the Pediatric
Quality of Life Inventory (PedsQL) score, the Pediatric
Glasgow Outcome Scale - Extended (GOS-E Peds) score,
digit span recall (a test of working memory), total blood
products (ml/kg) transfused over the initial 48 h of care
(children with torso injuries), intracranial hemorrhage
progression in first 24 h (children with brain injuries),
coagulation biomarkers, and adverse events.
We will assess neurocognitive functioning and other
quality-of-life measures using the PedsQL and the
GOS-E Peds 1 week, 1 month, 3 months, and 6 months
after ED presentation for all enrolled children (Fig. 3).
We will assess working memory using the digit span re-
call test 1 week, 1 month, 3 months, and 6 months after
ED presentation for all enrolled children 3 years and older.
Blood product transfusion will be calculated as the total
ml/kg blood products received from randomization to
48 h after randomization. Blood products in the calcula-
tion will include red blood cell components, platelet com-
ponents, plasma components, and cryoprecipitate. Prior
to study initiation, collaborating trauma surgeons, transfu-
sion medicine physicians, pediatric critical care physicians,
pediatric anesthesiologists, and pediatric emergency
medicine physicians will establish general guidelines for
indications and thresholds for blood product transfusion.
We will perform non-contrast cranial computed tomog-
raphy (CT) scans 24 (± 6) hours after randomization to
assess intracranial hemorrhage progression (for those who
have not received a second CT scan during the specified
time frame in the course of clinical care). We will exclude
those who received a neurosurgical intervention from as-
sessment of the 24 h CT scan. Additional brain-imaging
studies may be performed at the discretion of the treating
physician as a part of routine care. A study neuroradiolo-
gist, blinded to clinical data, will review cranial CT scans
and calculate intracranial hemorrhage progression
using the ABC/2 volume estimation [29]. Intracranial
hemorrhage will be assessed relative to the total brain
volume (calculated by the XYZ/2 volume estimation)
[30, 31]. We will also measure coagulation biomarker
tests before and after study drug infusion. These tests
include: kaolin activated TEG (measuring fibrinolysis as
the percentage of clot lysis at 30 min post-maximum clot
strength), d-dimer, tissue plasminogen activator (tPA),
plasmin-antiplasmin (PAP) complex, and plasmin gener-
ation. Parameters are performed at a central laboratory to
eliminate inter-assay variability and to standardize testing.
Safety outcomes will be assessed on the 7th day after
randomization or at hospital discharge (whichever
comes first) via review of the electronic medical rec-
ord and include:
 Thromboembolic disease: any venous or arterial
thrombosis on diagnostic imaging post-randomization
 Seizures occurring within the initial 24 h of study drug
administration: clinical or electroencephalogram-
documented
All study patients will be followed for 180 days after
randomization or death, whichever comes first, regard-
less of whether or not the patient has completed the
study intervention.
Data management and safety monitoring plan
The study Data Coordinating Center (at the University
of Utah) will create the electronic data capture system
and worksheets. Data will be entered via the internet
into the electronic data capture system. Worksheets and
study documents will be maintained in locked file cabi-
nets in locked offices at each site.
A trained site monitor will conduct site-monitoring
visits during the study period to ensure regulatory
compliance and patient safety, and to monitor the
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quality of data collected at each enrolling site. The
site monitor will provide each site with a written re-
port, and sites will be required to follow-up on any
deficiencies.
The study will have a Data Safety Monitoring Board
(DSMB) approved by the funding agency to advise the
sponsors and principal investigators regarding the
continuing safety of study patients and the continuing sci-
entific merit of the study. The DSMB will have a charter,
approve the protocol prior to implementation, and will re-
view interim analyses as applicable. The DSMB is respon-
sible for monitoring accrual of study patients, ensuring
adherence to the study protocol, assessing data quality,
reviewing the performance of individual clinical sites, and
Fig. 3 Schedule of evaluations. Abbreviations: Cr creatinine, CT computed tomography, GCS Glasgow Coma Scale, GOS-E Peds Pediatric Glasgow
Outcome Scale – Extended, Hb hemoglobin, ICP intracranial pressure, INR international normalized ratio, PedsQL Pediatric Quality of Life,
TBI traumatic brain injury, TXA tranexamic acid
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monitoring serious adverse events and other patient safety
issues. The DSMB will include a biostatistician, an ethicist,
a pediatric trauma surgeon, a pediatric neurosurgeon, a
patient advocate, and an emergency medicine physician.
Statistical considerations
As this study is a pilot trial to assess the feasibility of
study procedures, the study is not powered for a particu-
lar endpoint. We estimate that there will be 1.25 eligible
patients per site per month. This eligibility rate would
justify the feasibility of conducting a subsequent con-
firmatory clinical trial evaluating the safety and efficacy
of TXA in severely injured children. We will also evalu-
ate the feasibility of enrolling patients with parent or
legal guardian written informed consent only. If these
consent procedures are not feasible (particularly given
the 3 h from time of injury enrollment window and the
frequent absence of parents/guardians at the time of ED
presentation and study eligibility), we will apply to use
EFIC procedures if parents or legal guardians are not
available to provide written informed consent. We set a
priori thresholds for recruitment futility to convert to
the use of EFIC for patient enrollment. We will collect
detailed information on missed eligible patients to evalu-
ate the feasibility of consent processes to determine if
and when to initiate EFIC procedures. Ultimately our a
priori thresholds to convert to EFIC procedures were
met. Our trial protocol was revised to include EFIC pro-
cedures if parents or guardians are not available or able
to provide written informed consent.
Discussion
The primary objective of this pilot trial is to assess the
overall feasibility for a subsequent, confirmatory clinical
trial evaluating the efficacy of TXA in children with se-
vere hemorrhagic injuries. We designed the pilot trial to
mirror closely the subsequent confirmatory trial regard-
ing study design, interventional arms, procedures, and
outcome measures. Real-world implementation of the
study protocol will allow for assessment of various as-
pects of the pilot trial. This will provide critical informa-
tion on the number of eligible patients at study sites,
feasibility of timely consent and enrollment procedures,
and protocol adherence and variability of care. Although
we will not use the results of this pilot trial to estimate
sample size for the subsequent confirmatory trial, we
will assess the feasibility of obtaining various outcome
measurements to help inform the subsequent trial.
Clinical trials of critically ill children are typically more
challenging compared to similar trials in adults. Pediatric
trials draw from a smaller patient pool compared to
adult trials, making it more difficult to recruit adequate
numbers of subjects [32]. Issues regarding parental con-
sent and child assent often lead to variability in consent
processes and local ethic committee reviews [32, 33].
The many administrative tasks such as Institutional Re-
view Board (IRB) approvals and consortium agreements
can delay the start of projects and increase costs
[34–36]. These challenges have led to an inadequate
number of pediatric clinical trials [19]. Specifically
for the evaluation of TXA in trauma, there are currently
10 completed or open clinical trials in adults with
hemorrhagic trauma but none in children [37].
Although specific strategies have been recommended
to improve the efficiency of clinical trials, it is often diffi-
cult for investigators to identify all the potential obsta-
cles to optimize trial efficiency before actually starting
the trial [38–40]. Premature closure of phase III clinical
trials due to insufficient patient accrual wastes substan-
tial time and resources [41, 42]. Pilot trials, designed to
enroll a small number of patients with the primary goal
of assessing the feasibility of a subsequent phase III trial,
provide a less expensive alternative to embarking on a
costly, large-scale trial [43]. Pilot studies conducted prior
to definitive studies are particularly crucial in clinical
trials of critically ill children, which by nature are at
risk for low patient accrual and complex regulatory
requirements.
Previous pediatric pilot studies have provided clear an-
swers regarding the feasibility of subsequent phase III
trials. The Thrombolysis in Pediatric Stroke (TIPS) trial
was a phase I trial funded by the National Institute for
Neurological Disorders and Stroke (NINDS) to assess
treatment with intravenous tPA in children with acute
ischemic stroke [32]. Despite more than 200 meetings
and 3 years of preparation, the trial was prematurely
stopped due to lack of patient accrual. Only one patient
was enrolled in the 17 active sites (median time active,
9 months). Other issues identified in the trial included
delays for human subjects approval, costs for tPA stor-
age, and availability of tPA at study site pharmacies. In
contrast, the Therapeutic Hypothermia After Pediatric
Cardiac Arrest (THAPCA) trial conducted a pilot phase
to assess the feasibility of the larger scale trial [44]. The
National Heart, Lung, and Blood Institute (NHLBI) rec-
ommended an 18-month pilot phase prior to two larger
trials (one for in-hospital cardiac arrest and one for
out-of-hospital cardiac arrest) due to concerns regarding
the complexities of the trials, proposed costs, the feasi-
bility of the consent process, and the ability to obtain
long-term follow-up in critically ill children [44]. Ultim-
ately, the pilot phase demonstrated successful recruit-
ment (threshold attained 4 months ahead of schedule)
and included four protocol amendments to augment en-
rollment. The full-scale THAPCA trials were subse-
quently approved and completed [45].
We acknowledge certain limitations of our pilot trial.
We initially designed this trial using federal EFIC
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procedures; however, we were advised by the Food and
Drug Administration (FDA) to initiate the pilot trial en-
rolling only with written informed consent. After the
pilot study started, it became evident that most eligible pa-
tients did not have parents or legal guardians available to
provide written informed consent. The FDA subsequently
allowed EFIC procedures if eligible patients did not have
parents or legal guardians available to provide written in-
formed consent at the time of ED presentation and study
eligibility. The unavailability of parents or legal guardians
to provide written informed consent for injured children
in our trial is consistent with prior literature. Approxi-
mately half of children with moderate-to-severe TBI do
not have their guardian present in the ED in the first 3 h
after injury [46]. Future work is planned to qualitatively
and quantitatively evaluate parent or legal guardian per-
spectives regarding informed consent procedures for en-
rolling severely injured children into clinical trials.
Another potential limitation is that the results of the pilot
trial may not be generalizable to a much larger number of
clinical sites for the subsequent confirmatory study. How-
ever, because the pilot trial is being conducted at four clin-
ical sites, with each site bringing its own demographic,
geographic, and clinical diversity to the trial, we feel that
we will be able to better anticipate potential barriers for
the subsequent trial. Moreover, prior to the start of the
pilot trial, we will have established general guidelines for
blood transfusion and neurosurgical management that will
be standardized across clinical sites.
In conclusion, this pilot trial will be the first random-
ized clinical trial to evaluate TXA in children with severe
trauma and hemorrhagic injuries. The results of this
pilot trial will provide crucial preliminary information to
conduct a confirmatory trial.
Trial status
This manuscript is based on protocol version 2.03 (August
22, 2018). The trial opened for enrollment in July 2018
and we anticipate the trial will be completed by December
2019.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOCX 63 kb)
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